{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-275815","form_type":"8-K/A","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-06-18T20:06:18+00:00","discovered_at":"2026-06-18T20:07:00.329497+00:00","generated_at":"2026-06-18T20:15:07.452708+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene cuts workforce 50%, grants CEO performance options tied to detalimogene BLA and FDA approval milestones","bullets":["Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.","Performance-based equity retention awards (options and RSUs) approved June 16, vesting upon FDA acceptance of detalimogene BLA (by Sep 30, 2027) and FDA approval (by Dec 31, 2028).","CEO Ronald Cooper granted 400,000 performance-based options at $1.75/share, vesting 50% per milestone.","Retention costs: up to $1.7M cash and $2.8M non-cash stock comp.","Majority of expenses expected in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-275815","json":"https://secwatch.observer/filing/0001193125-26-275815.json","markdown":"https://secwatch.observer/filing/0001193125-26-275815.md","text":"https://secwatch.observer/filing/0001193125-26-275815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/0001193125-26-275815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/engn-20260616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:15:07.452708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80b317b2f132b5ef4418716ca210fd34c33ad812","claim":"enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense (approximately 50% of its workforce).","evidence_excerpt":"equity retention awards, which will vest, if at all, upon the achievement of the Milestones, the Company now estimates that it will incur restructuring costs of approximately $5.7 to $6.4 million in cash, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/0001193125-26-275815-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense"},{"label":"Headcount","value":"approximately 50% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}